Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I study of PRT-12396 is an open-label, multi-center, safety and efficacy study in patients with high-risk polycythemia vera (PV) and intermediate and high-risk myelofibrosis (MF)

Next Previous
Trial Profile

A Phase I study of PRT-12396 is an open-label, multi-center, safety and efficacy study in patients with high-risk polycythemia vera (PV) and intermediate and high-risk myelofibrosis (MF)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PRT 12396 (Primary)
  • Indications Myeloproliferative disorders; Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 03 Feb 2026 According to a Prelude Therapeutics media release, the company anticipates dosing the first patient by Q2 of 2026.
  • 16 Dec 2025 New trial record
  • 06 Dec 2025 According to a Prelude Therapeutics media release, The Company has completed GLP toxicology studies and anticipates filing the IND and initiating a phase 1 study in the first quarter of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top